174 related articles for article (PubMed ID: 26692526)
21. Radiation-induced nasopharyngeal ulcers after intensity modulated radiotherapy in primary nasopharyngeal carcinoma patients: A dose-volume-outcome analysis.
Li Y; Xu T; Qian W; Lu X; Hu C
Oral Oncol; 2018 Sep; 84():1-6. PubMed ID: 30115466
[TBL] [Abstract][Full Text] [Related]
22. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
[TBL] [Abstract][Full Text] [Related]
23. Who benefited most from higher cumulative dose of cisplatin among patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiation therapy? A retrospective study of 527 cases.
Ou X; Xu T; He X; Ying H; Hu C
J Cancer; 2017; 8(14):2836-2845. PubMed ID: 28928873
[TBL] [Abstract][Full Text] [Related]
24. A Dosimetric Comparison of Volumetric-modulated Arc Therapy and IMRT for Cochlea-sparing Radiation Therapy in Locally Advanced Nasopharyngeal Cancer.
Nanda S; Parida S; Ahirwar MK
J Med Phys; 2023; 48(3):248-251. PubMed ID: 37969150
[TBL] [Abstract][Full Text] [Related]
25. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases.
Lin S; Lu JJ; Han L; Chen Q; Pan J
BMC Cancer; 2010 Feb; 10():39. PubMed ID: 20146823
[TBL] [Abstract][Full Text] [Related]
26. Induction plus adjuvant chemotherapy, combined treatment with nimotuzumab, and intensity-modulated radiation therapy for N3 stage nasopharyngeal carcinoma: A pilot study.
Zhou L; Lin J; Chen J; Zhang S
J Cancer Res Ther; 2021 Dec; 17(7):1730-1735. PubMed ID: 35381746
[TBL] [Abstract][Full Text] [Related]
27. Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin.
Hua L; Chen S; Wei M; Shen Y; Long J; Lin Z; Meng Y; Guo C; Huang H; Tu X; Yao M
Cancer Biother Radiopharm; 2022 Feb; 37(1):2-10. PubMed ID: 33764811
[No Abstract] [Full Text] [Related]
28. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity.
Huang E; Teh BS; Strother DR; Davis QG; Chiu JK; Lu HH; Carpenter LS; Mai WY; Chintagumpala MM; South M; Grant WH; Butler EB; Woo SY
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):599-605. PubMed ID: 11849779
[TBL] [Abstract][Full Text] [Related]
29. Effects of Chemoradiation on Hearing in Patients with Head and Neck Malignancies: Experience at a Tertiary Referral Care Hospital.
Jain A; Banerjee PK; Manjunath D
Indian J Otolaryngol Head Neck Surg; 2016 Dec; 68(4):456-461. PubMed ID: 27833872
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
Kong L; Zhang YW; Hu CS; Guo Y
Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
[TBL] [Abstract][Full Text] [Related]
31. Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood Cancer.
Bass JK; Hua CH; Huang J; Onar-Thomas A; Ness KK; Jones S; White S; Bhagat SP; Chang KW; Merchant TE
J Clin Oncol; 2016 Apr; 34(11):1248-55. PubMed ID: 26811531
[TBL] [Abstract][Full Text] [Related]
32. Experience with combination of cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
He X; Ou D; Ying H; Zhu G; Hu C; Liu T
Eur Arch Otorhinolaryngol; 2012 Mar; 269(3):1027-33. PubMed ID: 21706324
[TBL] [Abstract][Full Text] [Related]
33. Postirradiation otitis media with effusion in nasopharyngeal carcinoma patients treated by intensity-modulated radiotherapy.
Hsin CH; Chen TH; Liang KL; Tseng HC; Liu WS
Laryngoscope; 2013 Sep; 123(9):2148-53. PubMed ID: 23835775
[TBL] [Abstract][Full Text] [Related]
34. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response.
Liu SL; Sun XS; Yan JJ; Chen QY; Lin HX; Wen YF; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Li XY; Lin C; Du YY; Yang ZC; Xiao BB; Yang JH; Tang LQ; Guo L; Mai HQ
Radiother Oncol; 2019 Aug; 137():83-94. PubMed ID: 31078941
[TBL] [Abstract][Full Text] [Related]
35. Experience of weekly cisplatin concurrent with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma patients with resistance to neoadjuvant chemotherapy.
Chen C; Chen T; Huang C; Wang J; Fei Z
Medicine (Baltimore); 2017 Nov; 96(44):e8434. PubMed ID: 29095283
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
37. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Wei Z; Zhang Z; Luo J; Li N; Peng X
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
[TBL] [Abstract][Full Text] [Related]
38. Frequency of Sensorineural hearing loss in chronic suppurative otitis media.
Ali Zaidi SS; Pasha HA; Suhail A; Qureshi TA
J Pak Med Assoc; 2016 Oct; 66(Suppl 3)(10):S42-S44. PubMed ID: 27895351
[TBL] [Abstract][Full Text] [Related]
39. Hypofractionated dose-painting intensity modulated radiation therapy with chemotherapy for nasopharyngeal carcinoma: a prospective trial.
Bakst RL; Lee N; Pfister DG; Zelefsky MJ; Hunt MA; Kraus DH; Wolden SL
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):148-53. PubMed ID: 20605352
[TBL] [Abstract][Full Text] [Related]
40. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy.
Haynes DS; O'Malley M; Cohen S; Watford K; Labadie RF
Laryngoscope; 2007 Jan; 117(1):3-15. PubMed ID: 17202923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
